Erratum to: Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

Davis, Robin L.; Bryson, Harriet M.

doi:10.1007/bf03257476

Cited by 97 publications

(130 citation statements)

References 0 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…For example, ciprofloxacin (PO and IV) ADR rates derived from ∼1985 to 1995 were ∼5% to 7%, 57 and levofloxacin, Ͻ3% in Japanese patients and Յ9.9% in North Americans. 56,58 These findings contrast with those of PO moxifloxacin (25% in US and German trials) and gatifloxacin (29% in US trials), which were investigated in the late 1990s. 59,60 Later (Phase IV) studies of levofloxacin in generally sicker and older patients (eg, those with AECB) report rates of 19% to 21% in Europe, 40,45 South America, 40,45 and South Africa.…”

Section: Adverse Effectsmentioning

confidence: 90%

Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review

Ball

2003

Current Therapeutic Research

View full text Add to dashboard Cite

Background: In recent years, fluoroquinolone research has focused on achieving several goals, including (1) enhanced potency against gram-positive cocci, notably Streptococcus pneumoniae, and anaerobes, while (2) maintaining potency against gram-negative pathogens, (3) optimizing pharmacokinetics and pharmacodynamics (PK/PD), and (4) minimizing potential adverse drug reactions through recognition and avoidance of structural configurations that have characterized earlier, reactive compounds.Objective: This review examines the efficacy and safety of fluoroquinolones and the specific clinical evidence regarding levofloxacin.Methods: Using published literature collected over time by the author, a review was conducted, focusing on the efficacy and safety profile of levofloxacin and other fluoroquinolones.Results: The newer fluoroquinolones have fulfilled many of the research goals described above. Levofloxacin has improved anti-gram-positive potency, PK/PD properties, a proven clinical trial record (particularly for communityacquired pneumonia [CAP]), and an excellent safety profile-in the context of the treatment of Ͼ250 million patients worldwide in the past decade. It is licensed for management of drug-resistant S pneumoniae infections in the United States and has gained widespread formulary acceptance and guideline inclusion. Studies assessing levofloxacin for CAP therapy show significant advantages over standard therapy, such as trends toward reduced IV therapy and length of hospitalization, reduced mortality, and significant associated cost reduction. In addition, levofloxacin has proved highly effective in acute exacerbations of

show abstract

Section: Adverse Effectsmentioning

confidence: 90%

Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review

Ball

2003

Current Therapeutic Research

View full text Add to dashboard Cite

show abstract

“…Taste disturbance is a known side effect of levofloxacin, but it is considered a rare side effect. 11 The metallic taste usually resolves after stopping the medicine. In this case, the metallic taste persisted even after levofloxacin was stopped.…”

Section: Mirtazapine Therapy For Dysgeusia In An Elderly Patientmentioning

confidence: 99%

Mirtazapine Therapy for Dysgeusia in an Elderly Patient

Padala¹,

Hinners²,

Padala³

2006

Prim. Care Companion CNS Disord.

View full text Add to dashboard Cite

“…Levofloxacin is the levo-isomer of ofloxacin. The activity of levofloxacin in vitro is generally better than that of ofloxacin against most organisms [11]. Levofloxacin can form a stable salt with acid, so its salts such as Levofloxacin lactate and Levofloxacin hydrochloride were usually used in clinic applications.…”

Section: Introductionmentioning

confidence: 99%

Influences of levofloxacin salts on the metabolism of Escherichia coli by microcalorimetry

Wang

Sun

et al. 2012

J Therm Anal Calorim

View full text Add to dashboard Cite

A microcalorimetric technique was used to evaluate the influence of both Levofloxacin lactate in sodium chloride injection (drug A) and Levofloxacin hydrochloride in sodium chloride injection (drug B) on the metabolism of Escherichia coli. By means of an isothermal calorimeter and ampoule method at 37°C, the power-time curves of E. coli growth were obtained under different conditions. The parameters such as the growth rate constant k, maximum power output P m , time t m corresponding to the maximum power output and inhibitory ratio I of these two drugs were obtained. The results reveal that the inhibitory abilities enhance with increasing concentrations of the two drugs. The critical growth concentration and the halfinhibitory concentration IC 50 were 0.15 and 0.079 lg mL -1 (for drug A), 0.13 and 0.061 lg mL -1 (for drug B), respectively. These results show the drug A has slightly better inhibitory effect on E. coli than that of drug B.

show abstract

Erratum to: Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

Abstract: Vol. 47, No.4, 1994, page 695: The second sentence in the second paragraph in the right-hand column should read. 'Administration of ferrous sulphate ... reduced the relative bioavailability of levofloxacin loomg to 81. 78 and 56% in healthy volunteers compared with controls, ... '.

Cited by 97 publications

References 0 publications

Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review

Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review

Mirtazapine Therapy for Dysgeusia in an Elderly Patient

Influences of levofloxacin salts on the metabolism of Escherichia coli by microcalorimetry

Contact Info

Product

Resources

About